Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
HH-2853 by Shanghai Haihe Biopharma for Soft Tissue Sarcoma: Likelihood of Approval
HH-2853 is under clinical development by Shanghai Haihe Biopharma and currently in Phase II for Soft Tissue Sarcoma. According to...
Data Insights
HH-2853 by Shanghai Haihe Biopharma for Sarcomas: Likelihood of Approval
HH-2853 is under clinical development by Shanghai Haihe Biopharma and currently in Phase II for Sarcomas. According to GlobalData, Phase...